OPRK1
ENSG00000082556
Target class
GPCR
Chromosome
8
Approved drugs
24
Clinical candidates (approved and in development)
32
- Approved drugs
- 24
- Clinical candidates (approved and in development)
- 32
- Chemical probe available
- Yes
- Target name
- OPRK1
- Gene name
- Opioid receptor kappa 1
- Gene symbol
- OPRK1
- Protein name
- Kappa-type opioid receptor (K-OR-1) (KOR-1)
- KOR
- OPRK
- Gene biotype
- Protein coding
- Gene family
- Opioid receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 9
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 4.08
- Tissue specificity (Gini)
- 0.805
- Tissue specificity (tau)
- 0.928
- KEGG gene identifiers
- hsa:4986
- R-HSA-375276
- R-HSA-418594
- R-HSA-9022699
- End position
- 53251637
- Start position
- 53225724
- Chromosome
- 8
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- Plasma membrane
- PubMed 12004055
- PubMed 22437504
- PubMed 7624359
- PubMed 8060324
- Tissue specificity (tau)
- 0.927997
- Expression inequality (Gini)
- 0.804816
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 4.08
- Brain - Hypothalamus
- 2.37
- Brain - Anterior cingulate cortex (BA24)
- 1.84
- Brain - Frontal Cortex (BA9)
- 1.58
- Brain - Caudate (basal ganglia)
- 1.55
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)4.08
- Brain - Hypothalamus2.37
- Brain - Anterior cingulate cortex (BA24)1.84
- Brain - Frontal Cortex (BA9)1.58
- Brain - Caudate (basal ganglia)1.55
- Brain - Amygdala1.28
- Brain - Cortex1.24
- Brain - Cerebellum1.04
- Brain - Cerebellar Hemisphere1.04
- Testis0.84
- Brain - Putamen (basal ganglia)0.62
- Prostate0.4
- Brain - Hippocampus0.4
- Brain - Substantia nigra0.28
- Adipose - Subcutaneous0.2
- Pituitary0.18
- Artery - Aorta0.12
- Heart - Atrial Appendage0.09
- Brain - Spinal cord (cervical c-1)0.09
- Colon - Sigmoid0.08
- Thyroid0.05
- Artery - Tibial0.03
- Colon - Transverse0.03
- Breast - Mammary Tissue0.02
- Minor Salivary Gland0.02
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007193
- GO:0007268
- GO:0007600
- GO:0031635
- GO:0038003
- GO:0051607
- GO:0005886
- GO:0016020
- GO:0004985
- GO:0005515
- GO:0038048
tachycardia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: tachycardia
- cardiovascular system
- nervous system
Evidence sourceinteraction with dopaminergic transmission and hallucination
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: interaction with dopaminergic transmission and hallucination
- cardiovascular system
- nervous system
Evidence sourcedizziness
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: dizziness
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased/increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased/increased heart rate
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased convulsions
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased/decreased eating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased eating
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased eating
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased eating
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264psychotomimetic effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: psychotomimetic effects
- cardiovascular system
- nervous system
Evidence sourcediuresis
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: diuresis
- cardiovascular system
- nervous system
Evidence sourcedecreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased cardiac contractility
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264hypotension
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypotension
- cardiovascular system
- nervous system
Evidence sourceincreased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264increased anxiety
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased anxiety
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased inflammation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased inflammation
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264dysphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: dysphoria
- cardiovascular system
- nervous system
Evidence sourceconfusion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: confusion
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264paresthesia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: paresthesia
- cardiovascular system
- nervous system
Evidence sourceantipruritic effects
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: antipruritic effects
- cardiovascular system
- nervous system
Evidence sourcedizziness
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: dizziness
- cardiovascular system
- nervous system
Evidence sourceanalgesia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: analgesia
- cardiovascular system
- nervous system
Evidence sourcedecreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased locomotor activity
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264decreased drinking
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased drinking
- nervous system
- cardiovascular
- gastrointestinal
PubMed 28216264
And 9 more, listed on the interactive page.
dizziness
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dizziness
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased gastrointestinal motility
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased gastrointestinal motility
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038tachycardia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: tachycardia
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038sedation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: sedation
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038increased urinary output
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased urinary output
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038decreased locomotion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased locomotion
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038dysphoria
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dysphoria
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038confusion
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: confusion
- cardiovascular system
- central nervous system
- gastrointestinal
PubMed 23197038
Related records
Trials (1,494)
- [11C]Carfentanil PET Study of GSK1521498
- 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans
- 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial
- A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
- A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
- A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.
- A Bundled Intervention to End Opioid Overdoses
- A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated
- A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused
- A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body
- A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS
- A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
- A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
- A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
- A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
- A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
- A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy
- A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery
- A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Drugs (44)
- Anileridine Kappa opioid receptor agonist
- Anileridine hydrochloride Kappa opioid receptor agonist
- Anileridine phosphate Kappa opioid receptor agonist
- Asimadoline Kappa opioid receptor agonist
- Aticaprant Kappa opioid receptor antagonist
- Axomadol Kappa opioid receptor agonist
- Benzhydrocodone Opioid receptors; mu/kappa/delta agonist
- Benzhydrocodone hydrochloride Opioid receptors; mu/kappa/delta agonist
- Buprenorphine Kappa opioid receptor agonist
- Buprenorphine hydrochloride Kappa opioid receptor agonist
- Butorphanol Kappa opioid receptor partial agonist
- Butorphanol tartrate Kappa opioid receptor partial agonist
- Cebranopadol Opioid receptors; mu/kappa/delta agonist
- Codeine Opioid receptors; mu/kappa/delta agonist
- Codeine phosphate Opioid receptors; mu/kappa/delta agonist
- Codeine polistirex Opioid receptors; mu/kappa/delta agonist
- Codeine sulfate Opioid receptors; mu/kappa/delta agonist
- Dextromoramide Opioid receptors; mu/kappa/delta agonist
- Dezocine Kappa opioid receptor antagonist
- Difelikefalin Kappa opioid receptor agonist